EUCTR2010-022010-32-GB进行中（未招募）1 期
A phase II single arm, multi-centre trial of triamcinolone with a GnRH analog for castration resistant prostate cancer - TRiCREST
Barts and The London NHS Trust0 个研究点目标入组 41 人开始时间: 2011年5月9日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 41
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1.Histologically confirmed adenocarcinoma of the prostate
- •2.Progressive disease despite castration with an elevated PSA >5ng/ml (testosterone <1.5nmol/l or failure of GnRH analogue with peripheral anti-androgen if non-castrate level on GnRH alone)
- •3.ECOG performance status (PS) 0-3 and considered by responsible consultant suitable to undergo treatment
- •4.Males aged greater or equal 18
- •5.Patients who are able to understand their participation in the study and give written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 41
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 41
排除标准
- •1.Contraindication to intramuscular injections
- •2.Unable to titrate medication for type 2 diabetes if deterioration in control on triamcinolone
- •3.Absolute contraindication to corticosteroids
- •4.Previous use of corticosteroids in prostate cancer
- •5.Previous chemotherapy for prostate cancer
- •6.Current participation in any other investigational drug study
- •7.History of a malignancy within 5 years except those treated with curative intent for skin cancer (other than melanoma)
研究者
相似试验
进行中（未招募）
不适用
Multicenter, single-arm, phase II study of the tri functional antibody catumaxomab (anti EpCAM x anti-CD3) administered intra- and postoperatively in patients with epithelial ovarian cancer - n.a.MedDRA version: 9.1Level: LLTClassification code 10033162Term: Ovarian epithelial cancer stage IIMedDRA version: 9.1Level: LLTClassification code 10033163Term: Ovarian epithelial cancer stage IIIMedDRA version: 9.1Level: LLTClassification code 10033164Term: Ovarian epithelial cancer stage IVMedDRA version: 9.1Level: LLTClassification code 10033161Term: Ovarian epithelial cancer stage IEpithelial Ovarian CancerEUCTR2006-004484-54-DEFresenius Biotech GmbH
进行中（未招募）
不适用
Multicenter, single-arm, phase II study of the tri functional antibody catumaxomab (anti EpCAM x anti-CD3) administered intra- and postoperatively in patients with epithelial ovarian cancer - n.a.Epithelial Ovarian CancerEUCTR2006-004484-54-ATFresenius Biotech GmbH
进行中（未招募）
1 期
A multi-centre 3-arm randomized phase II trial of BIBF 1120 versus BIBW 2992 versus sequential administration of BIBF 1120 and BIBW 2992 in patients with hormone-resistant prostate cancerChemo-naive hormone refractory prostate cancerEUCTR2005-005249-21-GBBoehringer Ingelheim Ltd.105
招募中
不适用
A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant and olanzapine for highly emetogenic chemotherapy in breast cancer.breast cancerJPRN-UMIN000038644Hoshi University Division of Applied Pharmaceutical89
尚未招募
3 期
CV638 ability to protect against homologous Vibrio cholerae 3008 virulent straicholera infectionVibrio InfectionsGram-Negative Bacterial InfectionsBacterial InfectionsWaterborne DiseasesEnvironmental IllnessCholeraRPCEC00000228Finlay Institute of Vaccines (IFV)120